Recombinant adeno-associated viruses (rAAVs) are currently considered the safest and
most reliable gene delivery vehicles for human gene therapy. Three serotype capsids …

As gene transfer with adeno-associated virus (AAV) vectors is starting to enter clinical
practice, this review examines the impact of vector capsid choice in liver-directed gene …

The adeno-associated virus (AAV) vector is a preferred delivery platform for in vivo gene
therapy. Natural and engineered variations of the AAV capsid affect a plurality of phenotypes …

All adeno-associated virus (AAV) vectors currently used in clinical trials or approved gene
therapy biologics are based on human or non-human primate AAVs. A major challenge for …

Adeno-associated viruses (AAVs) are small single-stranded DNA viruses that can package
and deliver nongenomic DNA for therapeutic gene delivery. AAV8, a liver-tropic vector, has …

The adeno-associated viruses (AAVs) display differential cell binding, transduction, and
antigenic characteristics specified by their capsid viral protein (VP) composition. Toward …

The single-stranded DNA (ssDNA) parvoviruses enter host cells through receptor-mediated
endocytosis, and infection depends on processing in the early to late endosome as well as …

Affinity-based purification of adeno-associated virus (AAV) vectors has replaced density-
based methods for vectors used in clinical settings. This method utilizes camelid single …

Adeno-associated viruses (AAVs) from clade E are often used as vectors in gene delivery
applications. This clade includes rhesus isolate 10 (AAVrh. 10) and 39 (AAVrh. 39) which …

Adeno-associated viruses (AAVs) are leading candidate vectors for human gene therapy.
AAV serotypes have broad cellular tropism and use a variety of cellular receptors. AAV …